PT1079849E - Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxica - Google Patents
Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxicaInfo
- Publication number
- PT1079849E PT1079849E PT99926330T PT99926330T PT1079849E PT 1079849 E PT1079849 E PT 1079849E PT 99926330 T PT99926330 T PT 99926330T PT 99926330 T PT99926330 T PT 99926330T PT 1079849 E PT1079849 E PT 1079849E
- Authority
- PT
- Portugal
- Prior art keywords
- medicines
- preparation
- cytotoxic activity
- hmg proteins
- hmg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT98MI001094A IT1299583B1 (it) | 1998-05-19 | 1998-05-19 | Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1079849E true PT1079849E (pt) | 2002-06-28 |
Family
ID=11380053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT99926330T PT1079849E (pt) | 1998-05-19 | 1999-05-19 | Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxica |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1079849B1 (pt) |
JP (1) | JP2002515445A (pt) |
AT (1) | ATE211391T1 (pt) |
AU (1) | AU4363199A (pt) |
DE (1) | DE69900756T2 (pt) |
DK (1) | DK1079849T3 (pt) |
ES (1) | ES2171086T3 (pt) |
IT (1) | IT1299583B1 (pt) |
PT (1) | PT1079849E (pt) |
WO (1) | WO1999059609A2 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7151082B2 (en) | 1999-02-11 | 2006-12-19 | The Feinstein Institute For Medical Research | Antagonists of HMG1 for treating inflammatory conditions |
US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
WO2001074420A1 (fr) * | 2000-04-05 | 2001-10-11 | Toray Industries, Inc. | Adsorbants pour proteines de la famille hmg et colonne de purification de liquide organique |
US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
US7220723B2 (en) | 2001-05-15 | 2007-05-22 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
ITMI20011986A1 (it) * | 2001-09-25 | 2003-03-25 | San Raffaele Centro Fond | Metodo e composizione per l'attivazione di cellule presentanti l'antigene |
WO2003051383A2 (de) * | 2001-12-19 | 2003-06-26 | Alcedo Biotech Gmbh | Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren |
GB0226251D0 (en) * | 2002-11-11 | 2002-12-18 | San Raffaele Centro Fond | Acetylated protein |
US7696169B2 (en) | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
CA2538763C (en) | 2003-09-11 | 2015-05-05 | Critical Therapeutics, Inc. | Monoclonal antibodies against hmgb1 |
WO2007001422A2 (en) | 2004-10-22 | 2007-01-04 | Medimmune, Inc. | High affinity antibodies against hmgb1 and methods of use thereof |
US8129130B2 (en) | 2004-10-22 | 2012-03-06 | The Feinstein Institute For Medical Research | High affinity antibodies against HMGB1 and methods of use thereof |
US20080311122A1 (en) | 2005-11-28 | 2008-12-18 | Medimmune, Llc | Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof |
DK2525817T3 (en) | 2010-01-21 | 2017-10-02 | Univ Arkansas | Vaccine vectors and methods for enhancing immune responses |
JP5746333B2 (ja) | 2010-06-09 | 2015-07-08 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー | カンピロバクター感染を減少させるワクチン及び方法 |
PT2956165T (pt) | 2013-02-14 | 2019-11-29 | Texas A & M Univ Sys | Composições e métodos de potenciação das respostas imunitárias frente a eimeria ou limitação de uma infeção por eimeria |
US10376571B2 (en) | 2013-03-15 | 2019-08-13 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to enteric pathogens |
EP3452069A4 (en) | 2016-05-03 | 2020-02-12 | The Board of Trustees of the University of Arkansas | Yeast vaccine vector with immunostimulating and antigenic polypeptides and method for using them |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62166897A (ja) * | 1986-01-20 | 1987-07-23 | Toyo Soda Mfg Co Ltd | 核内非ヒストン蛋白質に対するモノクロ−ナル抗体 |
EP0727487A1 (en) * | 1995-02-17 | 1996-08-21 | K.U. Leuven Research & Development | Multiple-tumor aberrant growth genes |
FR2739292B1 (fr) * | 1995-09-28 | 1997-10-31 | Rhone Poulenc Rorer Sa | Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations |
JP3018313B2 (ja) * | 1996-02-23 | 2000-03-13 | 雪印乳業株式会社 | 骨形成促進及び骨吸収防止剤 |
-
1998
- 1998-05-19 IT IT98MI001094A patent/IT1299583B1/it active IP Right Grant
-
1999
- 1999-05-19 DK DK99926330T patent/DK1079849T3/da active
- 1999-05-19 ES ES99926330T patent/ES2171086T3/es not_active Expired - Lifetime
- 1999-05-19 DE DE69900756T patent/DE69900756T2/de not_active Expired - Fee Related
- 1999-05-19 AU AU43631/99A patent/AU4363199A/en not_active Abandoned
- 1999-05-19 WO PCT/EP1999/003431 patent/WO1999059609A2/en active IP Right Grant
- 1999-05-19 PT PT99926330T patent/PT1079849E/pt unknown
- 1999-05-19 AT AT99926330T patent/ATE211391T1/de not_active IP Right Cessation
- 1999-05-19 EP EP99926330A patent/EP1079849B1/en not_active Expired - Lifetime
- 1999-05-19 JP JP2000549273A patent/JP2002515445A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2171086T3 (es) | 2002-08-16 |
WO1999059609A3 (en) | 2000-01-27 |
ITMI981094A1 (it) | 1999-11-19 |
WO1999059609A2 (en) | 1999-11-25 |
AU4363199A (en) | 1999-12-06 |
EP1079849A2 (en) | 2001-03-07 |
ATE211391T1 (de) | 2002-01-15 |
DK1079849T3 (da) | 2002-04-22 |
EP1079849B1 (en) | 2002-01-02 |
IT1299583B1 (it) | 2000-03-16 |
DE69900756T2 (de) | 2003-03-13 |
JP2002515445A (ja) | 2002-05-28 |
DE69900756D1 (de) | 2002-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1079849E (pt) | Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxica | |
ATE254630T1 (de) | Cyclosporine | |
BR9713404A (pt) | ésteres de n-(aril/heteroarilacetil) aminoácidos, composições farmacêuticas compreendendo os mesmos, e métodos para a inibição da liberação de peptìdeo beta-amilóide e/ou de sua sìntese por uso de tais compostos. | |
BR9714517A (pt) | Cicloalquila, lactama, lactona e compostos correlatos, composições farmacêuticas compreendendo os mesmos e processos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos | |
PT848720E (pt) | Antagonistas da actividade oncogenica da proteina mdm2 e sua utilizacao no tratamento de cancros | |
NO20010995D0 (no) | Cytotoksiske peptider modifisert med store eller lipofile rester | |
ES2103857T3 (es) | Peptidos ciclicos y su uso. | |
WO1999060013A3 (en) | Il-6 antagonist peptides | |
CA2280875A1 (en) | Remedies for lymphocytic tumors | |
ATE398630T1 (de) | Zyklische conotoxin-peptide | |
DK1228097T3 (da) | Antimikrobiel aktivitet af den förste kationiske humane lactoferrin-klynge | |
HUP0102975A2 (hu) | Kemotaxis-gátló Staphylococcus protein (CHIPS) és annak alkalmazása | |
BR0109279A (pt) | Antagonistas de lhrh, sua preparação e aplicação como medicamento | |
IL193310A0 (en) | Antibody directed against a polypeptide that interacts with parkin and pharmaceutical compositions comprising the same | |
BG103905A (en) | New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine | |
PL355852A1 (en) | Fragments of virus protein vp2 or 3 of the polyoma virus, used for transporting active ingredients | |
NO20000424D0 (no) | Streptograminer, deres fremstilling samt preparater inneholdende forbindelsene | |
ATE283279T1 (de) | Therapeutische inhaltsstoffe | |
AU2001278884A1 (en) | Anti-hiv and anti-tumor peptides and fragments of lysozyme | |
FI961505A0 (fi) | Uudet veren koaguloitumisjärjestelmässä terapeuttisesti aktiiviset peptidiyhdisteet, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset | |
BR9813102A (pt) | Derivados de ácido metilenobisfosfÈnico novos | |
WO1998051295A1 (fr) | Inhibiteur de la protease du vih-1, leur procede de production, et compositions medicinales | |
NZ509284A (en) | Tumour antigen peptide derived from SART-that binds to HLA-A24 antigen thereby facilitating recognition by a T call |